AstraZeneca on Thursday said its Covid-19 prophylaxis drug is 83% effective in reducing the risk of symptomatic Covid-19 infections six months after being given, signaling that the antibody cocktail could be used as an effective means of preventing severe disease in individuals who may not develop a robust immune response to Covid-19 vaccines....
A separate follow-up of the prophylaxis’ phase three trials showed that the drug eliminated the risk of severe Covid-19 and deaths among all recipients over six months after a dose was administered. The drugmaker noted that the trials used a 300-milligram dose of AZD7442 administered into the muscle to individuals who had not been exposed to Covid-19.
The antibody cocktail could prove to be an effective tool to protect people who may not develop a robust immune response after receiving Covid-19 vaccines.AstraZeneca’s chief of research and development, Mene Pangalos, said: “AZD7442 is the only long-acting antibody with Phase III data to demonstrate benefit in both pre-exposure prophylaxis and treatment of Covid-19 with one dose.”700,000. That’s the total number of doses of the antibody drug that AstraZeneca has agreed to supply to the U.S.
Did someone say 'cocktail'?